Introduction {#section6-1352458514564486}
============

Multiple sclerosis (MS) is a chronic disabling disease of the central nervous system.^[@bibr1-1352458514564486]^ Although comorbid physical and psychiatric comorbidities are increasingly recognized as relevant to clinical outcomes,^[@bibr2-1352458514564486][@bibr3-1352458514564486]--[@bibr4-1352458514564486]^ gaps in the understanding of the epidemiology of comorbidity in MS remain. Several studies have suggested that comorbid neurologic disorders such as migraine, seizure disorders and sleep disorders (such as restless legs syndrome) are more common than expected in the MS population when compared to the general population.^[@bibr5-1352458514564486],[@bibr6-1352458514564486]^ The impact of these conditions on disability, survival, and quality of life is poorly understood but existing studies suggest some neurologic comorbidities worsen these outcomes.^[@bibr7-1352458514564486],[@bibr8-1352458514564486]^ Even though knowledge of the burden of these conditions is relevant to clinicians, the estimates of the frequencies of these conditions are variable and study populations have often been small.

We aimed to systematically review the literature regarding the incidence and prevalence of comorbid seizure disorders and sleep disorders in MS. A secondary aim was to evaluate the quality of all included studies to make recommendations for future research.

Methods {#section7-1352458514564486}
=======

We conducted this review as part of a larger study on the worldwide incidence and prevalence of comorbidity in MS, but have divided these studies to allow for more detailed examination and discussion of findings. Herein we describe the findings for seizure disorders and sleep disorders.

The sleep disorders included were narcolepsy, periodic limb movements of sleep, restless legs syndrome, REM behavior disorder and sleep apnea. We did not review studies regarding sleep quality or insomnia due to challenges regarding the definitions of these conditions. We did not evaluate migraine as a recent systematic review and meta-analysis of headache was already available.^[@bibr9-1352458514564486]^ We reviewed the incidence and prevalence of cerebrovascular disease but these studies are reviewed in conjunction with those regarding comorbid cardiovascular and peripheral vascular disease.

As detailed elsewhere,^[@bibr10-1352458514564486]^ we developed separate search strategies for each comorbidity (Supplemental Appendix I). We reviewed the published literature and conference proceedings using PUBMED, EMBASE, SCOPUS, and Web of Knowledge for all years available through 20 November 2013. We also manually reviewed the reference lists of studies identified during electronic searches.

After review of the study objectives, two reviewers (RAM, NR) independently assessed whether unique abstracts identified met the inclusion criteria. We considered studies that were conducted in an MS population, included original data, specified the comorbidity of interest, clearly reported the incidence or prevalence of the comorbidity, and were published in English. If either reviewer selected the abstract it underwent full-text review, during which stage the articles were independently assessed by the two reviewers. We resolved disagreements by consensus.

One reviewer abstracted the data using a standardized data collection form and the findings were verified by the second reviewer. The data collection form (described in detail elsewhere) captured general study characteristics, as well as incidence and prevalence estimates.^[@bibr10-1352458514564486]^ We critically appraised each study using a standardized assessment tool utilized in another systematic review of the incidence and prevalence of MS, and awarded quality scores based on yes or no responses to 9 questions.^[@bibr10-1352458514564486]^ This process supported a qualitative assessment of study heterogeneity.

Statistical analysis {#section8-1352458514564486}
--------------------

For the quantitative analysis we used the *I*^2^ test to assess heterogeneity, and restricted this analysis to population-based studies. We conducted meta-analyses of these studies using a Microsoft excel spreadsheet developed for this purpose.^[@bibr11-1352458514564486]^ For studies in which zero events were recorded we employed a continuity correction of 0.5.^[@bibr12-1352458514564486]^

Results {#section9-1352458514564486}
=======

Seizure disorder (epilepsy) {#section10-1352458514564486}
---------------------------

### Search {#section11-1352458514564486}

We identified 490 unique citations (Supplemental Figure 1). After abstract screening and hand searching of reference lists, 49 articles met the criteria for full-text review, of which we excluded 17. Thirty-two unique studies were the subject of this review.^[@bibr5-1352458514564486],[@bibr7-1352458514564486],[@bibr13-1352458514564486][@bibr14-1352458514564486][@bibr15-1352458514564486][@bibr16-1352458514564486][@bibr17-1352458514564486][@bibr18-1352458514564486][@bibr19-1352458514564486][@bibr20-1352458514564486][@bibr21-1352458514564486][@bibr22-1352458514564486][@bibr23-1352458514564486][@bibr24-1352458514564486][@bibr25-1352458514564486][@bibr26-1352458514564486][@bibr27-1352458514564486][@bibr28-1352458514564486][@bibr29-1352458514564486][@bibr30-1352458514564486][@bibr31-1352458514564486][@bibr32-1352458514564486][@bibr33-1352458514564486][@bibr34-1352458514564486][@bibr35-1352458514564486][@bibr36-1352458514564486][@bibr37-1352458514564486][@bibr38-1352458514564486][@bibr39-1352458514564486][@bibr40-1352458514564486][@bibr41-1352458514564486]--[@bibr42-1352458514564486]^

### Study characteristics {#section12-1352458514564486}

The characteristics of the 32 included studies are shown in Supplemental Tables 2 and 3.^[@bibr5-1352458514564486],[@bibr7-1352458514564486],[@bibr13-1352458514564486][@bibr14-1352458514564486][@bibr15-1352458514564486][@bibr16-1352458514564486][@bibr17-1352458514564486][@bibr18-1352458514564486][@bibr19-1352458514564486][@bibr20-1352458514564486][@bibr21-1352458514564486][@bibr22-1352458514564486][@bibr23-1352458514564486][@bibr24-1352458514564486][@bibr25-1352458514564486][@bibr26-1352458514564486][@bibr27-1352458514564486][@bibr28-1352458514564486][@bibr29-1352458514564486][@bibr30-1352458514564486][@bibr31-1352458514564486][@bibr32-1352458514564486][@bibr33-1352458514564486][@bibr34-1352458514564486][@bibr35-1352458514564486][@bibr36-1352458514564486][@bibr37-1352458514564486][@bibr38-1352458514564486][@bibr39-1352458514564486][@bibr40-1352458514564486][@bibr41-1352458514564486]--[@bibr42-1352458514564486]^ The studies were conducted from 1935 to 2012. Most of the studies were conducted in Europe (central and Western) (16, 50%), followed by Asia (6, 18.7%), North America (5, 15.6%), and South America (2, 6.2%). Most studies relied on review of medical records including EEGs or clinical databases to establish the diagnosis of epilepsy, although a few relied on self-report or administrative data. Some studies did not distinguish between single seizures and epilepsy. Quality scores varied substantially from study to study, ranging from 0/9 to 8/8 (Supplemental Table 1, "Overview")^[@bibr10-1352458514564486]^ overall, but most studies had scores of greater than 5/8. Among population-based studies quality scores varied from 4/8 to 8/8. The most common limitations were the lack of a population-based design and confidence intervals for incidence and prevalence estimates.

### Incidence {#section13-1352458514564486}

Eighteen studies reported the incidence of epilepsy to range from 0.65% to 5.97% after MS onset in adult-onset MS.^[@bibr5-1352458514564486],[@bibr13-1352458514564486],[@bibr15-1352458514564486],[@bibr18-1352458514564486],[@bibr21-1352458514564486],[@bibr22-1352458514564486],[@bibr25-1352458514564486],[@bibr28-1352458514564486],[@bibr30-1352458514564486],[@bibr33-1352458514564486][@bibr34-1352458514564486][@bibr35-1352458514564486]--[@bibr36-1352458514564486],[@bibr38-1352458514564486],[@bibr39-1352458514564486],[@bibr41-1352458514564486],[@bibr42-1352458514564486]^ In pediatric-onset MS the incidence of seizures was 5.98%.^[@bibr23-1352458514564486]^ Among eight population-based studies the incidence ranged from 0.64% to 7.45% ([Figure 1](#fig1-1352458514564486){ref-type="fig"}, Supplemental Table 1). Heterogeneity among these studies was substantial (*I*^2^ = 98.2). The summary estimate of incidence was 2.28% (95% CI: 1.11--3.44%). Heterogeneity did not improve when the early study published in 1986 was removed (*I*^2^ = 98.5), and the summary estimate did not change appreciably (2.44%; 95% CI: 1.17--3.71%).

![Forest plot of the incidence of epilepsy in multiple sclerosis in population-based studies.](10.1177_1352458514564486-fig1){#fig1-1352458514564486}

### Prevalence {#section14-1352458514564486}

Twenty-four studies reported the prevalence of epilepsy to range from 0.89% to 8.06% (Supplemental Table 2).^[@bibr5-1352458514564486],[@bibr7-1352458514564486],[@bibr14-1352458514564486][@bibr15-1352458514564486][@bibr16-1352458514564486]--[@bibr17-1352458514564486],[@bibr19-1352458514564486][@bibr20-1352458514564486][@bibr21-1352458514564486]--[@bibr22-1352458514564486],[@bibr24-1352458514564486][@bibr25-1352458514564486][@bibr26-1352458514564486][@bibr27-1352458514564486][@bibr28-1352458514564486]--[@bibr29-1352458514564486],[@bibr31-1352458514564486],[@bibr32-1352458514564486],[@bibr34-1352458514564486][@bibr35-1352458514564486]--[@bibr36-1352458514564486],[@bibr38-1352458514564486],[@bibr40-1352458514564486],[@bibr42-1352458514564486]^ Among the 11 population-based studies the prevalence ranged from 0.89% to 7.48% ([Figure 2](#fig2-1352458514564486){ref-type="fig"}). Heterogeneity among these studies was substantial (*I*^2^ = 93.9); the summary estimate of prevalence was 3.09% (95% CI: 2.01--4.16%). Heterogeneity did not improve when the early study published in 1986 was removed (*I*^2^ = 94.3), and the summary estimate did not change appreciably (3.04%; 95% CI: 1.91--4.18%).

![Forest plot of the prevalence of epilepsy in multiple sclerosis in population-based studies.](10.1177_1352458514564486-fig2){#fig2-1352458514564486}

### Comparisons {#section15-1352458514564486}

Four studies compared the incidence of epilepsy in the MS population with that in a comparator population (Supplemental Table 3).^[@bibr5-1352458514564486],[@bibr13-1352458514564486],[@bibr33-1352458514564486],[@bibr35-1352458514564486]^ Of these, three studies found that the incidence of epilepsy was higher in the MS population while the fourth found no difference. Three studies compared the prevalence of epilepsy in the MS population with that in a comparator population.^[@bibr5-1352458514564486],[@bibr27-1352458514564486],[@bibr29-1352458514564486]^ All found that the prevalence of epilepsy was higher in the MS population.

Sleep disorders {#section16-1352458514564486}
---------------

### Search {#section17-1352458514564486}

We identified 144 unique citations (Supplemental Figure 2), of which 37 articles met the criteria for full-text review. Eighteen studies were the subject of this review.^[@bibr43-1352458514564486][@bibr44-1352458514564486][@bibr45-1352458514564486][@bibr46-1352458514564486][@bibr47-1352458514564486][@bibr48-1352458514564486][@bibr49-1352458514564486][@bibr50-1352458514564486][@bibr51-1352458514564486][@bibr52-1352458514564486][@bibr53-1352458514564486][@bibr54-1352458514564486][@bibr55-1352458514564486][@bibr56-1352458514564486][@bibr57-1352458514564486][@bibr58-1352458514564486][@bibr59-1352458514564486]--[@bibr60-1352458514564486]^

### Study characteristics {#section18-1352458514564486}

The characteristics of the 18 included studies are shown in (Supplemental Table 4).^[@bibr43-1352458514564486][@bibr44-1352458514564486][@bibr45-1352458514564486][@bibr46-1352458514564486][@bibr47-1352458514564486][@bibr48-1352458514564486][@bibr49-1352458514564486][@bibr50-1352458514564486][@bibr51-1352458514564486][@bibr52-1352458514564486][@bibr53-1352458514564486][@bibr54-1352458514564486][@bibr55-1352458514564486][@bibr56-1352458514564486][@bibr57-1352458514564486][@bibr58-1352458514564486][@bibr59-1352458514564486]--[@bibr60-1352458514564486]^ The time periods when the studies were conducted ranged from 1989 to 2011. Most of the studies were conducted in Europe (8, 44.4%), followed by North America (6, 33.3%), South America (2, 11.1%) and Asia (2, 11.1%). The studies used questionnaires (7, 38.9%), clinician-conducted interviews (7, 38.9%), and polysomnography (3, 16.7%) to identify sleep disorders, generally in MS clinic populations. None of the identified studies reported the incidence of these disorders, and none of the studies were population-based. Quality scores ranged from 2/9 to 7/9.

### Narcolepsy {#section19-1352458514564486}

Two studies reported the prevalence of narcolepsy to range from 0% to 1.6% (Supplemental Table 4).^[@bibr49-1352458514564486],[@bibr56-1352458514564486]^

### Periodic limb movements of sleep {#section20-1352458514564486}

One Italian study reported the prevalence of periodic limb movements of sleep to be 36% in an ambulatory MS population (Supplemental Table 5).^[@bibr46-1352458514564486]^

### Restless legs syndrome {#section21-1352458514564486}

Twelve studies reported the prevalence of restless legs syndrome to range from 14.4% to 57.5% (Supplemental Table 4).^[@bibr44-1352458514564486],[@bibr47-1352458514564486][@bibr48-1352458514564486][@bibr49-1352458514564486][@bibr50-1352458514564486][@bibr51-1352458514564486][@bibr52-1352458514564486][@bibr53-1352458514564486][@bibr54-1352458514564486]--[@bibr55-1352458514564486],[@bibr57-1352458514564486],[@bibr59-1352458514564486],[@bibr60-1352458514564486]^ Although the prevalence estimates varied widely, all studies consistently used the same diagnostic criteria from the International Restless Legs Syndrome Study Group, and the exclusion criteria used were similar in seven of the 12 studies. Three of these studies were conducted in Italy by the same group of investigators, two involving the same center and one involving multiple centers.^[@bibr51-1352458514564486][@bibr52-1352458514564486]--[@bibr53-1352458514564486]^

Seven studies compared the prevalence of restless legs syndrome in the MS population to a control population, and all found a higher prevalence of the syndrome in the MS population (Supplemental Table 5).^[@bibr44-1352458514564486],[@bibr46-1352458514564486][@bibr47-1352458514564486][@bibr48-1352458514564486][@bibr49-1352458514564486]--[@bibr50-1352458514564486],[@bibr52-1352458514564486],[@bibr57-1352458514564486],[@bibr60-1352458514564486]^ However, one study reported that the prevalence of restless legs syndrome did not differ between the MS population and a rheumatoid arthritis population.^[@bibr60-1352458514564486]^

### REM behavior disorder {#section22-1352458514564486}

Two studies reported the prevalence of REM behavior disorder to range from 2.22% to 3.2% (Supplemental Table 5).^[@bibr48-1352458514564486],[@bibr49-1352458514564486]^ The study with the lower estimate reported that this prevalence did not differ from the general population (0%), however the number of affected individuals in both populations was quite small (Supplemental Table 6).

### Sleep apnea {#section23-1352458514564486}

Five studies reported the prevalence of sleep apnea to range from 7.14% to 58.1% (Supplemental Table 5).^[@bibr43-1352458514564486],[@bibr45-1352458514564486],[@bibr47-1352458514564486],[@bibr49-1352458514564486],[@bibr58-1352458514564486]^ One of these studies used a questionnaire to identify those at high risk for obstructive sleep apnea (41.7%) but did not confirm this with polysomnography.^[@bibr45-1352458514564486]^ The other four studies confirmed diagnoses of obstructive sleep apnea with polysomnography, but one did so in a selected population referred for clinical evaluation of sleep disorders, thus this does not represent the prevalence of OSA in the general MS population.^[@bibr43-1352458514564486]^ This latter study also reported the prevalence of central sleep apnea to be 4.17%.

Discussion {#section24-1352458514564486}
==========

We reviewed the world literature regarding the incidence and prevalence of seizure disorders and sleep disorders. The incidence and prevalence of seizure disorders were evaluated in a large number of studies, eight of which were population-based. We also identified a large number of studies regarding sleep disorders, but most of these focused on the prevalence of restless legs syndrome, followed by sleep apnea. Most of the studies on seizure disorders were well-designed. Quality of the studies of sleep disorders was more variable, but the approaches to evaluating the most commonly assessed sleep disorder, restless legs syndrome, were consistent across studies.

In population-based studies, we found that the incidence of seizure disorders was 2.28%, while the prevalence was 3.09%. This exceeded the expected incidence and prevalence in the general population. Several of these studies reported seizures to occur at the onset of MS, and described the occurrence of both partial and generalized seizures. The increased risk of seizures may reflect the effects of inflammation or glial reactions around demyelinating lesions, or the direct effects of demyelinating lesions. The location of the demyelinating lesions appears to be an important factor.^[@bibr24-1352458514564486]^

Sleep disorders are common in the general population,^[@bibr61-1352458514564486]^ and have many adverse effects on other aspects of health.^[@bibr62-1352458514564486]^ Obstructive sleep apnea, for example, is associated with increased risks of hypertension, myocardial infarction, cerebrovascular disease, and daytime drowsiness. Persons with chronic medical conditions tend to be at increased risk of sleep disorders, and may be at risk of under-diagnosis.^[@bibr63-1352458514564486]^ People with MS are more likely to report symptoms of disrupted or inadequate sleep,^[@bibr64-1352458514564486]^ and poor sleep is associated with fatigue and reduced quality of life.^[@bibr65-1352458514564486]^ Thus interest is growing in the role of sleep disorders in MS.^[@bibr49-1352458514564486],[@bibr65-1352458514564486]^

In this review, we focused on specific sleep disorders but found that knowledge of the prevalence and incidence of these disorders remains limited. Only one study reported the prevalence of narcolepsy in a clinic population, while only two reported the prevalence of REM behavior disorder. We found a wide range of prevalence estimates for the best studied disorder, restless legs syndrome, reaching as high as 57.5%. In the absence of population-based studies, the true prevalence of this disorder in the MS population remains uncertain. While some studies suggested a higher prevalence in association with spinal cord disease,^[@bibr53-1352458514564486]^ variation in prevalence across sociodemographic and clinical characteristics remains poorly studied. Findings were consistent with respect to the increased risk of restless legs syndrome in the MS population as compared to the general population; this may not differ from other chronic disease populations. Estimates for the prevalence of obstructive sleep apnea were quite high, but this may reflect selection bias as studies were conducted in clinic-based populations and sometimes in populations with a clinical indication for polysomnography. Population-based studies are needed.

This review suggests that seizure disorders and sleep disorders are common in MS, but also highlights important gaps that exist in the epidemiological knowledge of these conditions in MS worldwide. Other than central-western Europe and North America most world regions are understudied. Future studies could be improved by using population-based designs, reporting age, sex and ethnicity-specific estimates of incidence and prevalence, and by standardizing findings to a common population.
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